Pancreatic ductal adenocarcinoma resists immunotherapy by building an immune-suppressive tumor fortress. This research explores how specific bacteria found in long-term survivors may reshape the tumor microenvironment, enhance immune checkpoint therapy, and help immune cells overcome suppression to attack pancreatic cancer more effectively.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.